In a CARACAL meeting, the European Commission has introduced the latest update of the ‘Rolling List of (groups of) substances for restriction’, which is part of the Restrictions Roadmap. HEAL has provided feedback to the updated rolling list and note concerns on the repeated delays in the implementation of restrictions of groups of substances that have been included in the Roadmap for several years.
The report provides a review of the scientific evidence that certain chemicals may be implicated in breast cancer, and focuses on the role of hormone disrupting chemicals. Particular reference is made to early life and multiple chemical exposures. Written by Professor Andreas Kortenkamp, Head of the Centre for Toxicology, School of Pharmacy, University of London, UK, the report has been peer reviewed by Professor Jan Ake Gustafsson (whose team discovered the oestrogen receptor-beta), Dr Julia Brody from the Silent Spring Institute, USA, and Prof Alastair M Thompson, Professor of Surgical Oncology at the University of Dundee.
The fully referenced report identifies important areas for further discussion not only within the breast cancer and wider medical community but also within that of chemicals regulation.
